The Latest Research Progress of Selinexor in the Treatment of Non-Hodgkin Lymphoma --Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 292-296, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-971139
ABSTRACT
Non-Hodgkin lymphoma (NHL) is a common lymphoid hematological malignancy, the treatment and prognosis of NHL have always been the focus of clinical attention. Chemotherapy is the main first-line treatment, but there is still no effective treatment for patients with poor response to chemotherapy, recurrence or progression within a short period of time after treatment, and new and effective drugs need to be developed clinically. As the only clinically validated oral selective inhibitor of nuclear export (SINE), Selinexor has been approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma and multiple myeloma, clinical attempts are being made to apply it to the treatment of other hematological malignancies.This article reviews the anti-tumor mechanism of Selinexor and the latest research progress in its application in NHL, and provides ideas for a more diverse, standardized and effective applications of Selinexor in NHL.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Triazoles
/
Linfoma no Hodgkin
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Transporte Activo de Núcleo Celular
/
Hidrazinas
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS